wellbutrin sr

About Andrx Andrx Corporation develops and commercializes: bioequivalent versions of controlled-release brand name pharmaceuticals, using wellbutrin sr its proprietary drug delivery technologies; bioequivalent versions of specialty, niche and immediate-release pharmaceutical products, including oral contraceptives; and brand name or proprietary controlled-release formulations of existing immediate-release or controlled-release drugs where it believes the application of Andrx's drug delivery technologies may improve the efficacy or other characteristics of those products. IMPAX currently has 20 applications pending at the FDA, including five tentatively approved, which address over $7 billion in U. The hospital pharmacists weren't aware of the XL formulation, which was new at the time, and XL wasn't clearly written in the order.
Wellbutrin sr in another case, a prescriber ordered Wellbutrin XR, 150 mg daily, although no such product exists. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of wellbutrin sr new information, future developments or otherwise.
Business Editors/Health/Medical Writers HAYWARD, Calif. --(BUSINESS WIRE)--Jan. Israel Makov, President and CEO of Teva, said: We are pleased to enter into this wellbutrin sr agreement with Andrx and IMPAX. The Court of Appeals did not make a final determination as to whether wellbutrin sr the Andrx products infringe the '798 patent. Bupropion HCl, ER 100mg tablets are the generic equivalent of Wellbutrin SR(R)(a) 100mg tablets. According to IMS Health, for the 12 months ended June 30, 2002, U. Such risks and uncertainties include, but are not limited to, IMPAX's ability to obtain sufficient capital to fund its operations, the difficulty of predicting FDA filings and approvals, consumer acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, IMPAX's ability to successfully develop and commercialize pharmaceutical products, IMPAX's reliance on key strategic alliances, the uncertainty of patent litigation, the availability of raw materials, the regulatory environment, dependence on patent and other protection for innovative products, exposure to product liability claims, fluctuations in operating results and other risks detailed from time to time in IMPAX's filings with the Securities and Exchange Commission. All three of these ANDA products employ patented or patent pending sustained release technologies developed by Andrx and these filings all contained Paragraph IV Wellbutrin sr certifications. Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Lane, Andrx Chief Executive Officer, stated: While we are disappointed with the decision of the Court of Appeals, we continue to believe that Andrx's wellbutrin sr generic versions of Wellbutrin SR and Zyban do not infringe any valid patents and we will continue to vigorously work towards resolving the litigation, and FDA and USP issues that have to date delayed their approval and marketing. Under the wellbutrin sr company's previously announced Exclusivity Transfer Agreement with Impax and a subsidiary of Teva, Andrx is entitled to a share of the profits derived from Teva's sale of this product for a 180-day period. Food and Drug Administration (FDA) granted final approval to the Company's Abbreviated New Drug Application for a Wellbutrin sr generic version of Wellbutrin SR(R) (Bupropion Hydrochloride) 200mg Tablets on December 3, 2004. Other Eon approvals include the generic form of the type 2 diabetes treatment Glucophage (metformin HCl) in 500 mg, 850 mg and 1,000 mg strength tablets from Bristol-Myers Squibb and Eli Lilly's antidepressant Prozac (fluoxetine) in 10 g and 20 g capsule and 10 mg tablet versions. The FDA has approved three preliminary ANDAs from Andrx Corp. Eon Labs is wellbutrin sr a generic pharmaceutical company specializing in developing, licensing, manufacturing, selling and distributing a broad range of prescription pharmaceutical products.